I am a
Home I AM A Search Login

Papers of the Week

2020 May 04

Acta Med Port



[Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].


Gomes N, Sibaud V, Azevedo F, Magina S
Acta Med Port. 2020 May 04; 33(5):335-343.
PMID: 32416756.


Immune checkpoint inhibitors revolutionized anti-neoplastic treatment. Recently, the European Medicines Agency and the United States Food and Drug Administration approved inhibitors of various immune checkpoints, namely the cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 and its ligand. Despite the added benefits in the treatment of several neoplasms, immune checkpoint blockade may also be associated with multiple immune-related adverse events.